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1. Summary
IDRC funded a trial of high titer (HT) measles vaccination in the Sudan from
1989-1992. This trial was designed to evaluate the effectiveness of high titer (Edmonston
Zagreb or Connaught; EZ and CN respectively) vs standard titer Schwartz (SCH) measles
vaccination (Phase I). The main study aims of Phase I were achieved but a second phase
of investigation became necessary when other HT trials reported increased mortality
associated with the higher titer vaccines. Dr Eric Hoskin's initial evaluation of the Sudan
data suggested that a similar trend towards increased mortality in the HT recipients was
also present in the Sudan trial. A site visit performed in 1993 suggested that a 5 year
immunologic follow-up study in the Sudan site would be particularly important because:
The Sudanese children had been enrolled more recently (vs other study sites)
The trial was placebo controlled
The trial was unique in its collection of morbidity data
The study was unique in the use of high titer Connaught vaccine
A random sample of the original study participants was approached to seek their
cooperation in the long-term immunologic follow-up. Over 3 months, 193 children were
recruited (73 EZ, 61 CN, 59 SCH). Blood samples were collected for determination of
antibodies directed against a variety of childhood pathogens. In addition, peripheral blood
mononuclear cells (PBMC) were frozen for phenotypic analysis and in vitro tests of
cellular immunity against childhood pathogens. Finally, the morbidity data collected over
the first three years of the original study was analyzed to identify possible trends in
morbidity associated with the HT vaccines.
The data we have generated can be summarized quickly and simply:
We performed more than 7,000 tests of immunologic function (>35 tests/specimen) and
found no consistent pattern of significant differences between the high and standard titer
vaccine recipients. The mortality associated with HT vaccines was greater in females than
males but we found no consistent differences between the sexes which could plausibly
account for the excess mortality observed. Finally, no significant morbidity could be
attributed to the HT vaccines in our review of more than 40,000 investigator visits over
the 36 month period after vaccination.
These data are immensely reassuring since:
earlier studies had demonstrated subtle immunologic changes in HT recipients
> 20 million doses of the HT vaccines were distributed throughout the world
before their use was suspended
These data suggest that the purported influence of HT vaccines on child survival is
idiosyncratic rather than a general immunologic insult with a 'dose-response' effect on
resistance to infection.
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2. Summary in Lay Terms
Standard measles vaccine does not protect children before 9 months of age, a time
when the complications of this infection may be particularly severe. In the late 1980's,
measles vaccines containing increased doses of the vaccine virus were introduced in an
attempt to protect these very young children. Although the vaccines worked well against
measles, several large studies reported that recipients of the high titer vaccines were at
increased risk of death from other illnesses for at least 2-3 years after vaccination. This
increased risk of death was greatest in girls and several studies reported subtle differences
in the immune systems of the high titer vaccine recipients up to 21/2 years after
vaccination.
We performed a detailed study of the immune status of a subset of children enrolled in a
trial of high tier measles vaccines in the Sudan 4-5 years after the suspect vaccination.
We evaluated a wide variety of immunologic parameters such as antibody production and
cellular recognition of microorganisms (immune memory) in these children. In all, we
performed more than 7,000 measurements in 193 of the original study participants and
found no differences between the high and standard titer vaccine recipients or between
the sexes.
The Sudan study was unique among the larger high titer vaccine trials since each child
was visited twice every month for 3 years after vaccination to evaluate the possible
benefits of the high titer vaccines. We were able to use these data to look for evidence of
possible harm (morbidity) associated with the high titer vaccines. We analyzed the data
from more than 40,000 home visits and could find no evidence of a harmful effect of the
high titer vaccines in either boys or girls.
Although the use of the high titer vaccines was suspended as soon as evidence of
increased mortality was presented (1993), the data generated in this study are reassuring
that no on-going harm is associated with the more than 20 million doses of these high
titer vaccines distributed throughout the world. These data establish that the immunologic
injury associated with high titer vaccines does not persist for more than 3-4 years after
vaccination. In addition, this study is the first to demonstrate that recipients of the high
titer vaccines were not 'sickly' after exposure to the vaccine. This observation suggests
that individual differences in the children receiving these vaccines may have contributed
to the observed increase in the risk of death.
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Overview of Grant-Supported Activities
Since the children enrolled in Phase I were growing up, there was considerable
pressure to collect as many samples as possible as quickly as possible in the summer of
1994. A graduate student (Fred Bertley) was assigned to the project and worked closely
with Dr SaIah during the summer and early fall (1994) to collect specimens from 193
children (see Section 4 for details of selection). The specimens were processed at the
University of Khartoum in the laboratory of Dr Hashim Ghalib and frozen for transport to
Canada. These specimens were hand-carried back to Canada and have been extensively
studied as Fred Bertley's immunology MSc thesis project (Section 5). On the basis of this
work, Mr Bertley has submitted his application to continue this line of study as a PhD.
The central findings of this study have been submitted in abstract form to the American
Society of Tropical Medicine (December 1996) and the first manuscript is in preparation.
Dr Micheal Libman visited The Sudan in late 1994 to help the field team organize the
mass of epidemiological data collected in Phases I and II of the study. This morbidity
data s now in the final stages of analysis (See Section 6 - anticipated submission of
manuscript - August 1996). Dr Au, a junior faculty member of the University of
Khartoum, was able to attend the Summer Epidemiology Program at McGill University
in 1995. Finally, the clinical material collected in Phase I of the Sudan study was
transferred to Canada and has already been useful to address questions of measles
immunology un-related to the central question of high titer vaccination (abstract
presented at 1996 Canadian Society for Immunology - manuscript in preparation).
It should be emphasized that although the grant was awarded for a 12 month
period, we have worked full-time with the samples collected for more than 18 months
now. We have only jij completed some of the more sophisticated analyses.
Selection of Children for Study in Phase II
I would like to acknowledge the assistance of Dr Theresa Gyorkos with this part
of the work (Clinical Epidemiology - McGill). She has been an invaluable member of
Fred Bertley's thesis committee.
Phase I of the Sudanese HI measles vaccine trial was conducted between 1989-92.
Children were recruited from 14 villages of the Umdawanband and Essailat rural
councils, approximately 50 kilometers from Khartoum. These villages range in size
from 800 to 5900 residents and there are no significant socio-economic, environmental
or nutritional differences between the children in the different villages. Over a ten-
month period, 510 five-month old infants were enrolled in the vaccine study. These
children were block randomized to receive one of three vaccine regimens:
Edmonston-Zagreb FIT at 5 months + Meningococcal vaccine at 9 months
Connaught HT at 5 months + Schwarz standard titer at 9 months
Meningococcal vaccine at 5 months + Schwarz standard titer at 9 months
There were no significant differences between the vaccine groups at the time of
recruitment to the initial trial or at the initiation of Phase II. In Phase II, 6 of the 14
villages were chosen at random and an attempt was made to recruit all of the children
in these villages. This was statistically permissible since there were no relevant
differences between the original study villages. We were able to recruit 193 children of
the 280 originally enrolled in the Phase I vaccine trial (69%; See Table 1). All of the
vaccine groups are well represented in this sample (Table 2).
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Table 1: Village Size and Number of Participants in Primary and Follow-Up Studies
Table 2: Distribution of Phase II Samples by Vaccine Group and Gender
Males Females Total
EZ CN Men EZ CN Men
41 28 33 32 33 26 193
EZ = Edmonston Zagreb
Men = Meningococcal (placebo)
CN = Connaught
Village Population #Children in #Children in % of
Vaccine Study Immunologic Study Vaccinees
Umdawanban 4800 96
Hawiela 800 11
Essailat 5900 106 88 83
Hasonab 1250 15
Hamda West 800 14
ElHashidl 1350 41 23 57
Abuzayd 1550 41 24 58
Baknab 1000 22 --
Fadnia 950 27 19 70
Sheikh 1800 37 27 73
MustafaBambonad 1700 28 12 43
Mahab 1700 46
Kutrang Kutang 2250 22
Mahab Tayba 550 4
Total (Phase I) 26,400 510
Total (Phase II) 280 193 69%
IDRC - Measles High Titter Immunologic Follow-up
Pa2e 6
5. Immunologic Data
Since measles continues to be a major killing infection in Sudanese children and
the children in the original trial were vaccinated at an early age, we used a range of assays
to evaluate both humoral and cellular components of measles specific immunity (Section
5.1). However, the reports of excess mortality in Hi' recipients implicated non-measles
pathogens as the causal agents. We therefore measured humoral and cellular immunity to
a range of other childhood pathogens as well (Section 5.2).
5.1 Measles-specific Immune Responses 4-5 Years after Vaccination
5.1.1 Humoral Responses to Measles Antigens
5.1.1.2 Total IgG ELISA
Total anti-measles antibody was evaluated by an ELISA developed in our
laboratory. The results of this assay are reported as milE-international units based
upon comparison with the WHO reference sera (Table 3). Levels> 200 mIU are
correlated with protection against infection. Virtually all of the children had
protective levels of anti-measles antibodies. While this finding was reassuring at
one level, it was also surprising since 12% of the EZ group had been seronegative
three months after vaccination. Although no measles cases were reported in the
study children during the 3 year morbidity follow-up (see Section 5), this
observation suggests that wild-type measles virus was circulating unrecognized in
the study communities.
As expected, the children vaccinated at 9 months of age had the highest
titers of anti-measles antibody. It was somewhat surprising that the children in the
Connaught group (vaccinated at 6 months and again at 9 months) did not have
higher titers although early vaccination has previously been reported to diminish
the antibody response to booster immunizations. Priming of these children for
cellular rather than humoral responses may explain this observation (see Section
8). Overall, girls in the high titer groups tended to have lower IgG levels than their
male peers but these differences did not reach statistical significance (Table 4).
Table 3
Total Measles-Specific IgG (ELISA)
Vaccine Group (n) IgG Titer
Control (61) 276±29
Edmonston-Zagrcb (73) 213 ±26
Connaught (59) 240 ± 35
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Table 4
Total Measles-Specific IgG (ELJSA)
Grouped by Gender
5.1.1.2 Neutralizing Antibodies by Svncvtium Inhibition
Neutralizing antibody assays are more time consuming and expensive than
standard ELISAs but are the 'gold standard' for measles serology. Syncytium
inhibition titers 32 are thought to be a reliable indication of protection against
measles.
The neutralizing antibody results were essentially identical to those generated by
ELISA (Table 5). There were also no differences in IgG subclass distribution or
IgG avidity between the groups or the sexes (data not shown).
Table 5
Measles-Specific eutralizing Antibody (SLA)
Grouped by Vaccine and Gender
p<.03 vs Control
5.1.2 Cellular Response to Measles Antigens
Cellular responses to measles antigens have never been measured before in
children in the developing world. Our laboratory has recently developed a
lymphoproli.ferative assay which made this possible in the Sudan HT children.
The results of this assay are reported as stimulation indices (SI) which is an
indication of antigen-specific T cell proliferation (divided by non-specific
proliferative activity). SI 3 are generally considered to indicate significant
lymphoproliferative activity. The measurement of cellular responses was
particularly important in these children because previous studies of immune
function in WI' recipients had suggested defects in cellular rather than humoral
IgG Titer
Vaccine Group (n) Male Female p
Concrol (6l) 235±30 315±48 .17
Edrnonston-Zagreb (73) 240±33 180±42
Connaiight (59) 288 ± 51 178 ±43 .12
SlATher
Vaccine Group (n) Male Female All
Control (61) 183±30 432±101 310±56
Edinonston-Zagreb(73) 225±55 190±41* 210±36
Connaught (59) 247 ± 44 211 ± 45 231 ± 31
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immunity. Since several different vaccines were used and 'effective' cell-mediated
immunity (CMI) would presumably be directed against wild-type measles
antigens, we tested the children's' blood cells using 3 different measles antigens: a
wild-type antigen (CHI-1), a partially attenuated vaccine strain (Edruonston B)
and a fully attenuated vaccine strain (Connaught).
The lymphoproliferative responses to the three measles antigen preparations were
similar and only the results of the challenge with wild type virus are presented
(Figure 1). The Sudanese children generally had low proliferative responses
compared with Canadian children 4-5 years after vaccination (mean Canadian SI
8-10; p < .001). The Connaught group tended to have the highest proliferative
responses although the differences did not reach statistical significance. There








Grouped v Vaccine and Gender
Coawol Edmonstoa- Connaug
Zaçeb
Conuo Edmons oa- ConaughtZaeb
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5.2 Immune Responses to Non-measles Pathogens at 4-5 Years of Ag.e
5.2.1 Humoral Responses to Non-measles Pathogens
ELISA assays were developed in our laboratory to measure specific antibody
responses to four of the major childhood pathogens: Clostridium tetani,
C'orynebacterium diphtheria, Bordatella pertussis and Haemophilus influenza.
International standard sera are available for the first two organisms and were used
to standardize the assays in milli-international units (mifi). A local standard was
used to control the other assays and results are reported in arbitrary units (U).
Vaccination histories for the study children (other than measles) were not
considered to be reliable and there was no active program of primary
immunization in the study region. Therefore, the immunity to non-measles
pathogens in the study children is considered to be predominantly 'natural'.
All of the study children had protective levels of antibodies directed against
tetanus (>0.01 mIU) and diphtheria toxins (>mITJ) .There were no statistically
significant differences between high and standard titer recipients for any of the
serologies (Table 6). Female NT EZ recipients tended to have more antibody
directed against tetanus toxoid and pertussis while male NT EZ recipients
generally had less antibody directed against pretties (Table 7).
Table 6
Antibody Titers against Non-Measles Pathogens
Grouped by Vaccine
Table 7
Antibody Titers against Non-Measles Pathogens
Group.ed by Vaccine & Gender
Titer
Antigen Control Ednionston-Zagreb Connaught
male female male ernale male female
Tetanus toxoid 74±9 54±10 64±8 62±7 71±9 40±9
Diphtheriatoxoid 15±2 14.5±2 13±2 14±2 13±2 11±2.5
BotdazellaPertussis 29±2 26±2 23±2 31±2 28±2.5 20±3




Tetanus toxoid 58 ± 7 63 ± 5 64 ± 8
Diphthetia toxoid 12±2 13 ± 1.4 15± 1.5
BoiaLeila Pertussis 25 ± 2 27 ± 1.5 28 ± 1.5
Haemophilus influenza 12±2 14±2 11.5 ± I
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5.2.2 Cellular Responses to Non-measles Pathogens
CMI has only recently been recognized as an important (if not critical) element of
the immune response to many childhood pathogens. We developed
lymphoproliferative assays for Clostridium tetani and purified protein derivative
(PPD; an indication of anti-tuberculosis activity). Again, results are expressed as
stimulation indices and SI 3 are considered to be significant.
In general, children responded well to tetanus toxoid and poorly to PPD. There
were no statistically significant differences between the groups or the sexes for
either of these cellular responses (Figure 3).
Figure 3












5.3 Other Immunological Parameters
In order to look for more subtle immunologic differences in the HT recipients, we
have recently completed data collection for an extensive FACS-based, phenotypic
analysis of a subset of the children (n = 75; twenty-five children from each
vaccine group). We used a panel of 30 monoclonal antibodies directed against
peripheral blood mononuclear cells subsets (CD4 and CD8 T cells, B cells,
monocytes, NK cells), activation markers and co-stimulatorv molecules (Table 8).
Table 8
Monoclonal Antibodies used for FACS Analysis
CD4 T Cells CD4SRA aaive cell marker B Cells CD23 activation marker
CD45RO memory cell marker ICAM-I adhesion molecule
CD4SRB transition phenotype CD 80 costunulaxory molecule
CD75 high affinity LL. receptor CD 86 costimultory molecule
CD2S low affinity IL- receptor CD2S low affinity IL-2 receptor
HLA-DR MHC class [I
CD3O Tn2 phenotype marker
CD2S cosumulatory molecule Monocytes ICAM-I adhesion molecule
CD8 CD4/CD8 ratio CD 80 cosumulatory molecule
CD71 transferrin receptor CD 86 costimultory molecule
LFA adhesion molecule
CD8 T Cells CD3S activation marker NK Cells CD38 activation marker
CD69 activation marker CD69 activation market
CD7S high affinity IL-2 receptor
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Although we have not yet completed the final analysis, it does not appear that
there are any major differences between the vaccine groups or between the sexes.
Minor differences between groups are present (eg: high NK cell expression of the
activation marker CD69 in HT EZ recipients; p <.04 vs control) but there is no
consistent pattern of either activation or suppression in the HT recipients.
6. Morbidity Follow-up
Phase I of the study included a regular (bi-monthly) follow-up to assess the
anticipated benefits of the high titer vaccines (eg: fewer days sick, economic benefits).
The regular visits were performed by village healthcare workers trained by the project.
Any child who was found to be ill was visited by one of the study pediathcians within a
week (generally within 3-4 days). It should be emphasized that these data were collected
prospectively to screen for potential benefit of the HT vaccines. Like all of the other HT
vaccine thals, Phase 1 was not designed to look for long-term adverse events. The
analysis we have performed is therefore a 'retro-fit' of the available data to address an
unanticipated outcome.
A tremendous amount of work on Dr Libman's part can be summarized with the
simple statement: There is no evidence that HT vaccination influences early childhood
morbidity. Measured outcomes included the number of days ill per month, the number of
illnesses per month (Figures 4 & 5), the number of days with fever, cough or diarrhea per
month, the number of investigator visits with fever, cough or diarrhea (Figures 6 & 7).
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This is the most convincing data generated to date that the impact of measles HT
vaccination on infant mortality was not due to cumulative morbidity. These data strongly
suggest that the HT effect was idiosyncratic in nature.
Possible Economic Analysis
We have performed a preliminary analysis of the economic data collected during
the periodic follow-up in Phase I with essentially negative results. This is not surprising
since the HT vaccine recipients in The Sudan appear to have neither benefited nor
suffered significantly compared with their peers who received standard titer vaccination.
Other Scientific Uses of the Sudanese Data
A large amount of clinical material and epidemiological information was collected
during Phase I and Phase II of the Sudan study. We have spent a good deal of time
organizing this material/data so that our study goals could be accomplished but also to
permit other, unanticipated uses. To date, we have identified one very exciting
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opportunity to study basic measles vaccine immunology using the Sudan data set. That is:
whether or not early measles vaccination can immunologically 'prime' individuals for a
better or different immune response. Our preliminary analysis of this question is outlined
below and was the subject of an abstract presented at the Canadian Immunological
Society meeting in Chanteclerc, Quebec (March 1996).
8.1 Exposure to Low Dose Measles Antigen may Bias towards Cellular Immunity
The presence of maternal antibodies makes measles vaccination in children <
9 months of age very difficult. Vaccination with the standard dose vaccine prior
to 9 months results in poor seroconversion rates. Furthermore, the antibody
response to revaccination in children first vaccinated at a time when maternal
antibodies were present is weaker than that observed in children who are
vaccinated only once after 9 months of age. Successful vaccination has
conventionally been defined in terms of the humoral response alone. However,
the immune correlates of protection against measles are not known and no
attention has been given to measles specific cell mediated immunity (CMI).
Since measles is an intracellular pathogen, CMI may be a important element in
controlling infection and the long-term maintenance of protection. Indeed,
patients with aggammaglobulemia recover uneventfully from measles infection,
while patients with defective CMI (e.g. HIV) suffer 50 - 100% mortality from
measles . Recent work has demonstrated that the dose of antigen can play an
important role in determining the type of immune response elicited (e.g.
humoral or cellular predominance). In vivo animal models have shown that low
doses of an antigen can prime the immune system for a cellular response upon
subsequent antigenic challenge. Also, naive CD4 T cells are susceptible to
biasing towards an antigen-specific Thi responses when exposed to intermediate
doses of a peptides. Although these experiments raise the possibility of directing
the induction of protective antigen-specific cellular responses, no similar human
data has been described. The Sudanese vaccine study allows the hypothesis that
early exposure of children to measles vaccine (i.e. in the presence of maternal
antibodies) might favor the production of measles specific CMI to be explored.
In the initial vaccine study in The Sudan, one third of the children received
Connaught vaccine (104.6 pfu) at 5 months and Schwarz standard titer vaccine
(10 pfu) at 9 months of age (Connaught; n = 170). The control children
received menningoccocal vaccination at 5 months and standard Schwarz
vaccine at 9 months (Control; n=170). In Phase II of the study (4-5 years after
vaccination), plasma and peripheral blood mononuclear cells were collected from
59 Connaught and 61 Control vaccine recipients.
Since Connaught children received their initial vaccination at 5 months of
age, it was predictable that a proportion would "fail" vaccination (i.e. fail to
develop significant antibody titers). The hypothesis of low dose antigen
biasingtowards a Thi response could therefore be tested by comparing the long-
term cellular and humoral responses generated by Connaught vaccine failures (n
= 12/59; 20%) with the immune responses generated by Control children (n = 61).
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8.1.1 Humoral Responses
The mean neutralizing antibody titer for Group 1 children tended to be lower than
that in Group 2 (SIA 178.739.3 vs 309.855.7) but this difference did not reach
statistical significance (p=.22).
8.1.2 Cellular Responses
In contrast, Group 1 children had significantly higher cellular responses than the
Group 2 children (SI 3.1 vs 1.4; p < .04).
These data suggest strongly that the early 'ineffective' exposure to measles antigens (in
terms of antibody production) biased the Group 1 children towards cellular rather than
humoral responses upon subsequent exposure to measles antigens. These data may have
significant implications for measles vaccination strategies throughout the world.
